Geri-Care Pharmaceuticals, Corp.
FDA inspection history in Lakewood, New Jersey, 2025
- 1
- Form 483
Every document, by year
- Form 483
2025: one Form 483.
The story so far
Built from the dates and citations on the documents themselves.
- 2025One Form 483, at Lakewood, New Jersey.
Cited most
Across all Geri-Care Pharmaceuticals observations on file
- 21 CFR 211.160General requirements1
- 21 CFR 211.165Testing and release for distribution1
- 21 CFR 211.192Production record review1
- 21 CFR 211.22(d)Responsibilities of quality control unit1
- 21 CFR 211.84Testing and approval or rejection of components, drug product containers, and closures1
The complete Geri-Care Pharmaceuticals file.
All 1 documents as original PDFs. For supplier audits, diligence and inspection prep.
Sites
Lakewood, New Jersey
One Form 483 · 2025 · 5 observations
Latest: Form 483, May 5, 2025 →
Documents
1 on file, newest first| Date | Document | Location | Observations | Price |
|---|---|---|---|---|
| 2025-05-05 | 483 Form 483 | Lakewood, New Jersey | 5 | $99 |
Investigators on these documents
FEI number 2435388 · most recent document May 5, 2025
About Geri-Care Pharmaceuticals, Corp.
How many FDA Form 483s has Geri-Care Pharmaceuticals, Corp. received?
FDA Intel has 1 Form 483 on file for Geri-Care Pharmaceuticals, Corp.; the most recent is dated May 5, 2025.
When was Geri-Care Pharmaceuticals, Corp. last inspected by FDA?
The most recent FDA inspection document on file for Geri-Care Pharmaceuticals, Corp. is a Form 483 dated May 5, 2025, for the site in Lakewood, New Jersey.
What did FDA cite at Geri-Care Pharmaceuticals, Corp.?
The regulations cited most in the observations on file for Geri-Care Pharmaceuticals, Corp. are 21 CFR 211.160 (General requirements), 1 time; 21 CFR 211.165 (Testing and release for distribution), 1 time; 21 CFR 211.192 (Production record review), 1 time.